Verrant recently retired as Senior Principal Scientist, Medical Digital & Technical Solutions Infectious Diseases at Janssen/Johnson & Johnson, where he led efforts implementing diagnostic solutions into clinical trials, and mentored early stage companies towards commercialization.
John Verrant is a leader in medical device development, with hands-on experience taking new technologies from platform development to product launch. He has authored over 320 publications, book chapters, and patents, and serves on several industry, academic, and editorial boards. His past roles include Vice President and General Manager of Corning Life Sciences, President of Bio-discovery at PerkinElmer, Executive Vice President for research and development at DiscoveRx Corp, and Vice President of the Center for Biological Research at Roche Pharmaceuticals. Richard Eglen is a distinguished veteran of the pharmaceutical, diagnostic, and biotech industries and has held numerous executive positions over the past 40 years. Richard Eglen as Chairman, and John Verrant and Dr. "Their insights will significantly help us leverage the progress we've made, and guide us towards bringing innovative testing solutions to market." "We are honored to be working with a team of respected individuals whose scientific and industry expertise directly relate to the work we have underway," commented Randolph Storer, CEO and co-founder of LamdaGen. The inaugural SAB members represent a distinguished set of experts who bring a depth of leadership, innovation and product commercialization experience in the life science, diagnostic, pharmaceutical and food safety industries. JPRLog - LamdaGen Corporation, an emerging technology company with a powerful, plasmonic platform for rapid diagnostic/detection testing, is pleased to announce the members of its newly-formed Strategic Advisory Board (SAB). LAuRA Plasmonic Sensing Platform MENLO PARK, Calif.
0 kommentar(er)
